Patient derived xenograft (PDX) models provide a predictive preclinical model for the evaluation of an agent’s efficacy prior to entering the clinic. The CrownBio collection of pancreatic PDX contains over 100 models, including models of both North American and Asian descent. More
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.